Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

t is being prepared.

?These three Phase II clinical trials sponsored by NCI are components of a clinical trials program designed to identify signals of clinical activity of ispinesib across multiple tumor types,? stated Dr. Andrew A. Wolff, Cytokinetics Senior Vice President of Clinical Research and Development and Chief Medical Officer. ?Although these three trials did not meet the protocol-specified criteria for progression, we are encouraged by the anti-cancer activity of ispinesib observed to date in three other Phase II trials in breast, ovarian and non-small cell lung cancers. Based on these data, we plan to move forward in further clinical development of ispinesib with a focused approach to the potential treatment of breast cancer with ispinesib.?

Clinical Trials of Ispinesib

Ispinesib has been the subject of a broad Phase II clinical trials program under the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the NCI. GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second- or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer, and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these trials has been closed. To date, clinical activity with ispinesib has been observed in breast cancer, in non-small cell lung cancer, and ovarian cancer with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. In this clinical trial, The best overall responses observed with ispinesib were partial responses in 4 of 45 evaluable patients as measured by the RECIST criteria. Responses were confirmed by independent radiology review and were seen in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/2/2008)...S, October 2 /- Pharmaleads has obtai...authorization to perform a single,ascending dose P...,treatment of neuropathic pain., Neuropathic pain...ted,prevalence in the world,s population of up to ...y causes such as shingles, herpes, diabetes,antiv...
(Date:10/2/2008)...KHOLM, October 2 /- Athera Biotechnol...today that they have entered into a,collaboration ...r the,prevention or treatment of cardiovascular in...he recent publication of work by Athera,scientific...he Karolinska,Institutet. The research links natur...
(Date:10/2/2008)...ta Indicate Dual Modes of Action and Synergy with ...l/ -- Access Pharmaceuticals, Inc.,(OTC Bulletin B...cal,studies on Angiolix showing that by blocking l...ffect as well as a direct anti-proliferative effec...uman breast cancer (MX-1),Angiolix had a signific...
(Date:10/1/2008)...port the therapeutic potential of Amylin,s integra...sity pharmacotherapy, SAN DIEGO, Oct. 1 /PRNewswi...daq: AMLN ) today announced that new data for its...the 2008 Annual Scientific Meeting of The,Obesity ...y,s annual,meeting is one of the largest and most ...
Breaking Medicine Technology:Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 1Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 2Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 3Computer Aided Detection in Screening Mammography Enhances Performance of a Single Reader 11794 4The Best Way to Stoke Your Valentines Fire 3A Dont Light Up 11792 1The Best Way to Stoke Your Valentines Fire 3A Dont Light Up 11792 2Orqis 28R 29 Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meet 11789 1Orqis 28R 29 Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meet 11789 2Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 1Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 2Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings Inc to Halyard Capital LLC 11786 3
...3, 2007-- Ongoing therapeutic cancer vaccine,trial...,patient’s immune system to shrink tumors --... tend to live longer and respond,better to subsequ...cer Research, a journal of the American Associatio...nstitute researchers asks a,fundamental question: ...
...--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotec...e,completion of apricitabine,s controlled, double ...egment of its Phase IIb trial.,Patients have now p... (weeks 24 to 48) and will continue to receive 800... treatment regime.,The Company expects to release ...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:10/6/2008)... LegalView recently posted detailed infor...the potentially serious side effects caused by the...g the drug,s potential side effects are the develo...s for young adult and child patients. , ...-- LegalView, the number one resource for everythi...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rec... Garden Valley, Texas October 6, 2008 -- www.seamo...al provider of communications services to remote l...ss to the FoxNews channel via satellite to Mercy S...rica Mercy. The Africa Mercy is the world,s large...
(Date:10/6/2008)...rmany, Oct. 6 /PRNewswire-FirstCall/ -- SAP AG (NY... joined SAP as senior vice president,of the Health...ective,August 1, 2008, Mr. Papandrea will help dri...strategic software solutions to healthcare,organiz... in conjunction,with the 3rd annual Ambassadors Di...
(Date:10/5/2008)...MA...Free prescription drug samples distributed to...hysicians from Cambridge Health Alliance and Hasbr...st to look at free drug sample use among children,.... , The authors, who also serve as researchers ...dical School of Brown University, found that child...
Breaking Medicine News(10 mins):Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3Health News:Free drug samples carry risks for children 2
...d problem solving, visual spatial processing, memo...severe alcoholism. Smoking is much more prevalent ...t the possible neurocognitive effects of cigarette... studied, despite evidence that long-term smoking ...
...e nephron-sparing surgery (NSS) is considered appr...s; however, it is still difficult to detect high n...ecific tumor markers have been identified for RCC,...is a variable predictor of lymph node and distant ...
...dings released by University of Florida doctors cl...fely avoid surgery after radiation therapy if they...r the cancer is under control or not, the research...d at the annual meeting of the American Society fo...
...or Vittorio Demicheli an Italian epidemiologist as...ving the use of Mumps, Measles and Rubella (MMR) v...k between MMR vaccination and autism or bowel dise...ots in children’s may cause Autism. This review lo...
Other Medicine News:Health News:A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma 2Health News:MMR Vaccination not linked to Autism 2
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Merocel Ophthalmic Products provide the surgeon with superior fiber free products for unparalleled fluid control and safe cleaning of fine microsurgical instruments. The exclusive Merocel material is
Medicine Products: